

**PHASE III TRIAL OF ANTICANCER AGENT HALAVEN[®] IN
SOFT TISSUE SARCOMA SHOWS OVERALL SURVIVAL BENEFIT
IN PRIMARY ENDPOINT**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that in a Phase III clinical trial (Study 309) of its in-house discovered and developed anticancer agent eribulin mesylate ("eribulin," Brand name: Halaven[®]) in patients with soft tissue sarcomas, eribulin demonstrated a statistically significant extension in overall survival (O.00056n

drug as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

[Notes to editors]

1. About Halaven (eribulin mesylate)

Halaven, a halichondrin class microtubule dynamics inhibitor with a novel mechanism of action, belongs to a class of antineoplastic agents, the halichondrins, which are natural products isolated from the marine sponge *Halichondria okadae*. It is believed to work by inhibiting the growth phase of microtubule dynamics without affecting the shortening phase and sequestering tubulin into nonproductive aggregates.

Halaven was first approved as a treatment for breast cancer in the United States in November 2010, and is now approved in nearly 60 countries worldwide, including Japan and countries in the Americas, Europe and Asia. In Japan, Halaven has been approved to treat inoperable or recurrent breast cancer and was launched in the country in July